LOS Homepage

Advocacy

Move the Needle on Key Policy Priorities

Check Back for Updates!

FDA Grants Accelerated Approval to Zanidatamab-hrii for Select Cases of Biliary Tract Cancer

FDA Approves Updated Drug Labeling for Fludarabine phosphate Under Project Renewal

FDA Approves Revumenib for Relapsed or Refractory Acute Leukemia With a KMT2A Translocation

FDA Approves Obecabtagene autoleucel for Adults With Relapsed or Refractory B-cell Precursor Acute Lymphoblastic Leukemia

Anemia in Focus: The Challenge of Identifying Myelodysplastic Syndromes (MDS)

Is It Time to Cancel the Term “A Cure for Cancer”